menu
    • menu
    [{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"PD-1-targeted IL-2 Therapy","moa":"PD-1 inhibitor\/IL-2 receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bonum Therapeutics \/ Roche","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Therapeutics \/ Roche"},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"PDL1 Dependent INF-alpha Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Bonum Therapeutics \/ Roche Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Therapeutics \/ Roche Venture Fund"}]

    Find Clinical Drug Pipeline Developments & Deals by Bonum Therapeutics

    Menu

    Bonum Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bonum Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bonum Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PDL1 Dependent INF-alpha Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Roche Venture Fund

                            Deal Size : $93.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally...

                            Details : The Series A financing will allow Bonum to apply the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 15, 2022

                            Lead Product(s) : PDL1 Dependent INF-alpha Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Roche Venture Fund

                            Deal Size : $93.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bonum Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bonum Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PD-1-targeted IL-2 Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

                            Details : The acquisition will give Roche rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $250.0 million

                            September 07, 2022

                            Lead Product(s) : PD-1-targeted IL-2 Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth